

Nutritional and Botanical Approaches to Antiaging

**Chris D. Meletis, N.D.,
with Nieske Zabriskie, N.D.**

As the human population ages and increases in longevity, study of biological aging is emerging. According to the Centers for Disease Control and Prevention, for 2003, an estimated 35.9 million Americans were over the age of 65 and more than 25 percent of this population was in fair-to-poor health.¹ The mechanism of cellular aging is elusive and many theories have been proposed to explain the decrease in physiologic function that occurs with aging. As a result of increased risks of disease and mortality, decreases in quality of life, and rising health care costs, aging and longevity research is necessary to address problems related to aging. A wide range of nutrients and interventions have been shown to decrease cellular aging and age-related disease.

Theories of Aging

There are several theories of cellular aging. These theories are not mutually exclusive, and many complement each other. Aging was initially believed to be a result of genetically programmed cell death. Subsequently, it was proposed that aging might be a result of accumulation of cellular damage and mutation. Given that evidence has surfaced suggesting that aging may be a result of cellular damage, this implies that interventions to influence aging are possible.

Oxidative Stress and Free Radicals

Damage caused by free radicals is the most popular and universal theory of cellular aging. These highly reactive molecules are formed in many biochemical reactions as well as being introduced via exogenous exposures. Free radicals react with molecules causing damage and mutations, and have been implicated in many disease processes.²

Studies indicate that an increase in the accumulation of oxidative damage increases functional deficits during aging, and treatments that decrease oxidative damage have been shown to delay age-related loss of function.³ Other evidence suggests that increases in oxidative stress cause increases in inflammatory mediators, leading to age-related inflammatory diseases, such as arthritis, atherosclerosis, osteoporosis, and dementia.⁴

Mitochondrial Damage

Mitochondria produce most of the energy used by the body in the form of adenosine triphosphate (ATP). Oxidative phosphorylation provides the majority of ATP production via the electron transport chain. Aging has been shown to decrease the efficiency of mitochondrial oxidative phosphorylation. Specifically, aging decreases cellular energy production, impairs substrate oxidation, and increases the production of free radicals.⁵ Loss of muscle mass and function seen with aging is associated with mitochondrial damage in muscle cells.⁶

Studies indicate that aging is associated with a decrease in number and increase in size of mitochondria, making them less efficient with age.⁷ Small amounts of reactive oxygen species (ROS) are formed via energy production that regulates some cellular functions, and that can act as a second messenger for transcription factors.⁸

Cells have several antioxidant enzymes to prevent excess ROS from causing damage. Enzymes required for oxidative phosphorylation and antioxidant enzymes decrease with age as the number of cells completely lacking the enzyme cytochrome oxidase increases.⁹ In addition, mitochondrial DNA is more susceptible to free-radical damage and mutation than nuclear DNA.¹⁰

Research indicates that mitochondrial DNA mutation in post-mitotic cells begins accumulating in individuals after the mid-30s.¹¹ These mutations may lead to impaired protein transcription and translation causing the decrease in cellular respiration. Studies have shown that human cells with increased levels of mutant mitochondrial DNA produce less ATP and release increased levels of ROS.¹²

Studies also show a decrease in mitochondrial membrane potential with aging. This causes an increase in proton leakage and a decrease in ATP production, thus affecting the efficiency of cellular respiration.¹³ Mitochondrial defects and the resultant decline in mitochondrial function are implicated in the induction of apoptosis. Increased oxidant levels have been shown to cause an increase of events such as increased activation of the mitochondrial permeability transition pore leading to an increase in the release of proapoptotic proteins from the mitochondria.¹⁴

Telomeres

Telomeres are repeat sequences at the ends of eukaryotic chromosomes that provide protection and stabilization. Telomeres generally shorten with each replication because of the inability of

DNA polymerase to copy the lagging DNA strand. Telomerase is a reverse transcriptase that synthesizes the telomere. Most human cells are deficient in telomerase, allowing the attrition of the telomere. Short telomeres activate irreversible cell-cycle arrest (cellular senescence and apoptosis).¹⁵

Cancer cells have been shown to upregulate telomerase, prolonging the lifespan of the tumor cells.¹⁶ Approximately 90 percent of cancer cells have high levels of telomerase activity.¹⁷ Oxidative damage has been shown to accelerate telomere shortening, and antioxidants have been shown to slow telomere attrition.¹⁸ Research suggests that telomere length is a highly heritable trait and that telomeres are longer in women than in men.¹⁹ Obesity and smoking have also been shown to decrease telomere length.²⁰

A study done with long-term estrogen and progesterone hormone therapy in postmenopausal women showed that longer telomeres appeared in women on hormone replacement than in women without hormone therapy.²¹

In addition, individuals with mood disorders have been shown to have significantly shorter telomeres, possibly providing the link between mood disorders and increased morbidity and mortality.²²

Another study revealed that women with the most chronic and highest levels of perceived stress had lower telomerase activity and shorter telomeres.²³ Research has also shown that telomere shortening in vascular cells is associated with endothelial dysfunction and atherosclerosis formation.²⁴

Neurologic and Endocrine Dysfunction

This theory suggests that aging is caused by endocrine dysfunction, which is common in elderly people. Changes in hormonal secretion, loss of receptor sensitivity to stimulatory or inhibitory stimuli, anatomic changes of endocrine glands, and altered transport of hormones occur in aging.²⁵

Many hormones decrease with aging. Studies have shown that melatonin secreted from the pineal gland (responsible for regulation of circadian rhythms) decreases with age. Specifically, increasing age is directly proportional to decreasing levels of plasma melatonin and delayed melatonin elevation.²⁶

Growth hormone decreases at approximately 14 percent per decade. After age 60, growth hormone is decreased by approximately 50–70 percent compared with levels in the third and fourth decade of life.²⁷

Steroid hormones, such as estrogen and testosterone, also decrease with age.²⁸ Interestingly, estrogen has been shown to upregulate telomerase activity.²⁹ Animal studies have also demonstrated that testosterone may decrease telomerase activity.³⁰

Crosslinkages

Proteins and other macromolecules can undergo crosslinking reactions. Proteins that undergo these reactions become less elastic, less soluble, and less digestible by enzymes. This theory suggests that large molecules undergo crosslinkage when exposed to a crosslinking agent causing cellular damage and cell death. Advanced glycosylation endproducts (AGEs) are formed by a reaction between reducing sugars and biologic proteins. Glycated proteins are stable and accumulate over time. AGEs react with molecules creating crosslinkages.

Potential Antiaging Supplements

- Dimethylaminoethanol (DMAE)
- Dehydroepiandrosterone (DHEA)
- Growth hormone
- Melatonin
- Carnosine
- Niacinamide
- Coenzyme Q10
- Resveratrol
- Glutathione
- Vitamin E
- Vitamin C
- β -carotene
- α -lipoic acid.
- *Astragalus membranaceus* (astragalus)
- *Ginkgo biloba* (ginkgo)

Evidence suggests that, although antioxidants may not be able to prolong life, they may improve quality of life as they provide benefit for patients who have cancer and age-related diseases, such as atherosclerosis, neurodegenerative, and ocular diseases.^a

^aFrom ref. 96.

These reactions have been implicated in the pathology of several diseases. Hyperglycemic conditions such as diabetes have an increase in glycosylation of proteins, which may explain the increase in chronic diseases that occur with these conditions.³¹ Collagen crosslinkage has been shown to cause increased stiffness in cartilage possibly leading to decreased resistance to damage and osteoarthritis.³²

Decreases in vascular and myocardial elasticity, and hypertension, endothelial dysfunction, and atherosclerosis formation are associated with increased AGE accumulation.³³ Protein crosslinking is also found in the brains of individuals with Alzheimer's disease.³⁴ Research also suggests that cataracts may be associated with crosslinkage in eye lenses.³⁵

Nutritional and Supplement-Based Antiaging Interventions

Calorie Restriction

Calorie restriction is one of the most supported interventions in aging and longevity research. Studies with numerous animal types have demonstrated that calorie restriction increases longevity and decreases age-related diseases. Calorie restriction is widely studied in attempts to define which biochemical pathways are affected by fasting and the induced stress response.

Research with humans indicates that calorie restriction modulates energy metabolism, reduces free-radical production, and alters endocrine function.³⁶ A study with monkeys demonstrated that a 30 percent reduction in calories lowered core body temperature and decreased energy expenditure.³⁷ Calorie restriction also increases the levels of nicotinamide adenine dinucleotide (NAD)-dependent protein deacetylases (known as sirtuins), which are involved in energy metabolism and gene silencing, and are associated with increased longevity.³⁸ Specifically, these

proteins deacetylate and inactivate p53, allowing cells to bypass apoptosis and survive DNA damage, giving cells time to repair damage.³⁹

Another study showed that calorie restriction decreased mitochondrial proton leakage, cellular oxygen consumption, and ROS production in rat muscle.⁴⁰ In addition, insulin and tri-iodothyronine are decreased with calorie restriction.⁴¹ Insulin replacement reverses the beneficial effects of calorie restriction in the mitochondria by increasing ROS formation.⁴²

A study with rats also revealed that calorie restriction decreases the age-related decline of the glutathione and thioredoxin systems, supporting the antioxidant function of calorie restriction.⁴³ This intervention also reduces DNA damage and mutations and increases DNA repair by increasing the activity and reliability of DNA polymerases, which decline with aging.⁴⁴

Cancer and age-related immunologic defects, which are associated with DNA damage, also decrease with calorie restriction.⁴⁵ Calorie reduction decreases the release of leptin, a peptide hormone secreted from adipocytes. This alteration in leptin levels has been shown to activate the adrenal axis while suppressing the thyroid, gonadal, and somatotrophic axes.⁴⁶

Studies have also shown that calorie restriction alters levels of heat-shock proteins, which are protective for cells and which are induced by stressful stimuli. Heat-shock proteins decrease with age, and dietary restriction has reversed this process in the cardiac tissue of animals.⁴⁷

Dimethylaminoethanol

Dimethylaminoethanol (DMAE), also known as deanol, is a naturally occurring substance that has been studied as a possible antiaging therapy that can also improve cognitive function. DMAE is the precursor to choline and may increase acetylcholine levels.⁴⁸

DMAE inhibits production of the age-related pigment lipofuscin, which accumulates in all aging tissues. This is significant because cells with increased lipofuscin cause lysosomes to perform poorly, which leads to increased accumulation of poorly functioning mitochondria and increased ROS production.⁴⁹ Evidence also suggests that DMAE decreases the extent of crosslinking of proteins possibly by acting as a free-radical scavenger.⁵⁰

Dehydroepiandrosterone

Dehydroepiandrosterone (DHEA) is a steroid hormone produced primarily in the adrenal cortex as well as in the liver, brain, and testes. DHEA is the precursor to androstenedione, which is then converted to androgens and estrogen. DHEA peaks at approximately age 20 and declines steadily with age.⁵¹

DHEA levels have been studied relative to numerous age-related diseases. Research has suggested that low DHEA levels may be correlated with cardiovascular disease (CVD), cancer, obesity, immune deficiency, insulin resistance, and depression.⁵²

Evidence has shown that DHEA supplementation of 50 mg per day for 1 year improved bone mineral density in both men and women over age 60.⁵³ DHEA supplementation has been shown to decrease visceral and subcutaneous fat and insulin levels in elderly men and women.⁵⁴ Studies have also revealed the antiatherogenic effects of short-term supplementation when 50 mg of DHEA per day was given to elderly individuals.

In addition, this research has shown increased platelet cGMP production, signifying nitric oxide (NO) production, decreased levels of plasminogen activator inhibitor, decreased levels of low-density lipoprotein (LDL) cholesterol, and increased levels of testosterone and estradiol.⁵⁵

Data obtained in a study indicate that DHEA sulfate (DHEAS) is decreased in elderly patients with congestive heart failure (CHF) compared with age-matched controls. This study also showed that the decline in DHEAS is proportionate to the severity of CHF and is associated with oxidative stress.⁵⁶

Recent evidence also indicates that DHEA improves muscle mass and strength in elderly individuals when combined with weight-lifting exercise compared with weight lifting alone.⁵⁷

A study of DHEA supplementation with individuals ages 45–65 with midlife-onset minor or major depression showed a significant improvement in the participants' Hamilton Depression Rating Scale scores compared with baseline after 6 weeks of treatment.⁵⁸

Growth Hormone

Growth hormone (GH) is secreted by the pituitary gland and exerts its effects either directly or indirectly via insulin-like growth factor-1 (IGF-1). GH and IGF-1 decrease significantly with age. Low IGF-1 levels have been associated with numerous age-related diseases, such as atherosclerosis, CVD, dementia, and sarcopenia.⁵⁹

IGF-1 can stimulate NO production from endothelial and vascular smooth-muscle cells, indicating a vascular protective function.⁶⁰ IGF-1 also has antiapoptotic and neuroprotective effects.⁶¹ In addition, serum IGF-1 levels are correlated significantly with muscle strength and physical performance.⁶²

Melatonin

Melatonin* is a hormone secreted from the pineal gland primarily at night and regulates circadian rhythms. Both total output and rhythmicity of melatonin decrease with age.⁶³ Melatonin provides protection from oxidative damage by functioning as a free-radical scavenger and regulates the expression of antioxidant enzymes.⁶⁴ This hormone also exhibits immune-stimulating benefits.

Age-related decline of humoral, innate, and cellular immunity is implicated in the increase in disease, physical degeneration, and cancer in elderly patients. Studies indicate that melatonin enhances cellular and innate immunity. The hormone stimulates progenitor cells of granulocytes, natural-killer cells, macrophages, and several cytokines.⁶⁵ Melatonin also increases the production of T-helper cells.⁶⁶

In addition, melatonin affects mitochondrial function directly. The free-radical activity of melatonin limits decline in intramitochondrial glutathione and decreases mitochondrial protein and DNA damage, allowing for more efficient electron transport chain function and increased ATP production. This activity

*EDITOR'S NOTE: For more information on melatonin, see the article on pages 282–291 by Amy Fitzpatrick, M.S., R.D.

blocks the decline in mitochondrial-membrane potential, which would cause opening of the mitochondrial transition pore and possibly induce the apoptotic cascade.⁶⁷

Studies indicate that melatonin has neuroprotective qualities and can slow the progression of Alzheimer's disease.⁶⁸ Melatonin also produces anticancer activity and has been shown to inhibit tumor-cell proliferation, stimulate tumor-cell differentiation and apoptosis, and inhibit tumor-cell uptake of linoleic acid at both physiologic and pharmacologic doses.⁶⁹ Decreased melatonin synthesis caused by increased light during the night has been shown to increase cancer-cell proliferation.⁷⁰

Carnosine

Carnosine is a dipeptide composed of β -alanine and L-histidine. It is found in high concentrations in skeletal muscle, cardiac muscle, and the brain.⁷¹ Human studies indicate that muscle carnosine levels decrease significantly with age, demonstrating a 63 percent decrease from age 10 to age 70.⁷²

Studies have shown several biochemical functions of carnosine suggesting antiaging properties. Carnosine acts as an antioxidant decreasing lipid oxidation and protecting membranes from free-radical damage as well as chelating reactive metals.⁷³ Carnosine has been shown to extend the lifespan of human fibroblasts, possibly because of the dipeptide's ability to slow telomere attrition and decrease damage to telomere DNA.⁷⁴

Studies indicate that carnosine can prevent crosslinking, glycation, protein carbonyl group formation, and the formation of AGEs, which play a role in aging and age-related disease.⁷⁵ Carnosine has also been shown to inhibit toxic effects of amyloid peptide, malondialdehyde, and hypochlorite to cells.⁷⁶

Niacinamide

Niacinamide (vitamin B₃), also known as nicotinamide, is the amide form of niacin and is necessary for numerous biochemical reactions. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). NAD and NADP are essential for oxidation-reduction reactions and ATP synthesis. Niacinamide is necessary for modulating cell metabolism, cell longevity, and mitochondrial-membrane potential.⁷⁷

Research shows that nicotinamide can reverse aging phenotypes in aging human fibroblasts. This study revealed that aging cells exposed to nicotinamide showed increased replicative potential and histone acetyltransferase activity, suggesting restoration of altered gene expression.⁷⁸

There is supportive evidence that niacin may be protective against age-related cognitive decline and Alzheimer's disease, and that higher niacin intake from the diet produces a slower annual rate of cognitive decline.⁷⁹ Niacin supplementation has also been shown to provide benefit for patients with age-related CVDs, such as atherosclerosis, hyperlipidemia, and coronary artery disease.^{80,81}

Coenzyme Q10

Coenzyme Q10 (CoQ10), or ubiquinone, is a compound made by the body and primarily functions as an antioxidant, membrane stabilizer, and a cofactor in cellular respiration. CoQ10

supplementation has been shown to ameliorate cardiovascular diseases, neurologic disorders, and possibly cancer. Studies indicate that CoQ10 supplementation in individuals with CHF improved ejection fraction, stroke volume, and cardiac output.⁸² CoQ10 has also been shown to decrease systolic hypertension, with 12 weeks of supplementation producing a mean decrease in systolic blood pressure of 17.8 mm Hg.⁸³ Additional research showed that 120 mg of CoQ10, given for 28 days after acute myocardial infarction, decreased angina, arrhythmias, poor left ventricular function, total cardiac events, and oxidative free radicals.⁸⁴

CoQ10 appears to be promising for slowing functional decline in individuals with neurodegenerative diseases caused by mitochondrial dysfunction or oxidative damage such as Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and Friedreich's ataxia.⁸⁵ CoQ10 supplementation is also effective as a migraine prophylactic therapy.⁸⁶ In addition, some evidence supports CoQ10 as having immunomodulating and anticancer actions.⁸⁷

Resveratrol

Resveratrol is a natural polyphenol found in high concentrations in red-grape skins and berries. It is widely studied because of its antioxidant, anti-inflammatory, anticancer, and possibly antiaging properties. Evidence suggests that resveratrol increases lifespan in simple organisms and mimics calorie restriction by activating sirtuin.⁸⁸

Additional studies indicate that resveratrol may provide chemoprotective action by inhibiting tumor initiation, promotion, and progression by possibly downregulating proinflammatory mediators.⁸⁹ Resveratrol has also been shown to be cardioprotective, suppressing platelet aggregation, inhibiting LDL oxidation, and reducing myocardial damage during ischemia-reperfusion.⁹⁰ Research suggests that age-related neurologic diseases, such as stroke, ischemia, Huntington's disease, and possibly Alzheimer's disease may be ameliorated with resveratrol.⁹¹

Glutathione

Glutathione is a tripeptide made primarily in the liver. This tripeptide acts as a free-radical scavenger, modulates DNA synthesis and immune function, and detoxifies xenobiotics and their metabolites.⁹² Plasma glutathione levels are significantly decreased in elderly people and the glutathione in this population is in a more oxidized state, implying increased oxidative stress.⁹³

Evidence suggests that oxidative stress and glutathione deficiency play a role in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease.⁹⁴ Increased oxidation of glutathione is found with cigarette smoking, chemotherapy, and age-related diseases, such as cardiovascular disease and type 2 diabetes.⁹⁵

Other Antioxidants

Numerous additional antioxidants have shown antiaging benefits such as vitamin E, vitamin C, β -carotene, and α -lipoic acid. Almost all age-related diseases are caused or exacerbated by oxidation and free-radical damage.

Evidence suggests that, although antioxidants may not be able to prolong life, they may improve quality of life as they provide benefit for patients who have age-related diseases, such as cancer, atherosclerosis, neurodegenerative, and ocular diseases.⁹⁶

Studies have also shown that supplementation, using antioxidants, such as vitamins C and E, zinc, selenium, and β -carotene, improves leukocyte function and restores redox balance in prematurely aging animals.⁹⁷ In addition, antioxidants such as vitamins C and E and carotenoids decrease DNA damage and malignant transformation in cells, and are associated with lower risks of cancer, ischemic heart disease, and cataracts.⁹⁸

Botanical Antiaging Interventions

Astragalus

Astragalus membranaceus (astragalus) is a botanical frequently used because of its antioxidant activity. Research suggests that this herb inhibits free radicals, decreases lipid peroxidation, and increases antioxidant enzymes.⁹⁹ Studies also suggest that astragalus provides cardioprotective and immune-stimulatory effects.^{100,101} Evidence indicates that astragalosides exert antiaging effects on mice by delaying senility, improving brain function, and improving cellular immunity.¹⁰²

Ginkgo

Ginkgo biloba (ginkgo) leaf has antioxidant, anticancer, and free-radical scavenging actions as well as improving microcirculation and protecting neurons from oxidative damage. The herb also decreases platelet aggregation and induces NO.¹⁰³ Evidence suggests that ginkgo has cardioprotective activity and may provide benefit for patients who have arterial and venous insufficiency as well as preventing thrombosis.¹⁰⁴ In addition, ginkgo is well-known for its ability to slow age-related cognitive functional decline and Alzheimer's disease.¹⁰⁵

Conclusions

Much research is underway to understand the aging process and study potential antiaging interventions. As the population ages it is important to investigate potential therapeutics to slow aging and improve quality of life. According to research, interventions that produce antioxidant activity seem to be a common denominator in antiaging treatment. □

References

- Centers for Disease Control Fast Stats. Online document at: www.cdc.gov/nchs/fastats/older_americans.htm Accessed August 18, 2006.
- Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: Basic mechanisms, functional effects and pathological considerations. *Am J Physiol Regul Integr Comp Physiol* 2006 Aug 17;e-pub ahead of print.
- Martin I, Grotewiel MS. Oxidative damage and age-related functional declines. *Mech Ageing Dev* 2006;127:411–423.
- Chung HY, Sung B, Jung KJ, et al. The molecular inflammatory process in aging. *Antioxid Redox Signal* 2006;8(3–4):572–581.
- Lesnefsky EJ, Hoppel CL. Oxidative phosphorylation and aging. *Ageing Res Rev* 2006;5:402–433.

- Dirks AJ, Hofer T, Marzetti E, et al. Mitochondrial DNA mutations, energy metabolism and apoptosis in aging muscle. *Ageing Res Rev* 2006;5:179–195.
- Sato T, Tauchi H. The formation of enlarged and giant mitochondria in the aging process of human hepatic cells. *Acta Pathol Jpn* 1975;25:403–412.
- Felty Q, Xiong WC, Sun D, et al. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. *Biochemistry* 2005;44:6900–6909.
- Cortopassi GA, Wong A. Mitochondria in organismal aging and degeneration. *Biochim Biophys Acta* 1999;1410:183–193.
- Richter C. Oxidative damage to mitochondrial DNA and its relationship to ageing. *Int J Biochem Cell Biol* 1995;27:647–653.
- Fahn HJ, Wang LS, Hsieh RH, et al. Age-related 4977 bp deletion in human lung mitochondrial DNA. *Am J Respir Crit Care Med* 1996;154(4pt1):1141–1145.
- Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. *Exp Biol Med (Maywood)*. 2002;227:671–682.
- Harper ME, Monemdjou S, Ramsey JJ, Weindruch R. Age-related increase in mitochondrial proton leak and decrease in ATP turnover reactions in mouse hepatocytes. *Am J Physiol* 1998;275(2pt1):E197–E206.
- Mather M, Rottenberg H. Aging enhances the activation of the permeability transition pore in mitochondria. *Biochem Biophys Res Commun* 2000;273:603–608.
- Shin JS, Hong A, Solomon MJ, Lee CS. The role of telomeres and telomerase in the pathology of human cancer and aging. *Pathology* 2006;38:103–113.
- Blasco MA. Telomeres and human disease: Ageing, cancer and beyond. *Nat Rev Genet* 2005;6:611–622.
- Ahmed A, Tollefsbol TO. Telomerase, telomerase inhibition, and cancer. *J Anti-Aging Med* 2003;6:315–325.
- von Zglinicki T. Oxidative stress shortens telomeres. *Trends Biochem Sci* 2002;27:339–344.
- Aviv A. Telomeres, sex, reactive oxygen species, and human cardiovascular aging. *J Mol Med* 2002;80:689–695.
- Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. *Lancet* 2005;366:662–664.
- Lee DC, Im JA, Kim JH, et al. Effect of long-term hormone therapy on telomere length in postmenopausal women. *Yonsei Med J* 2005;46:471–479.
- Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: Preliminary support for a chronic stress model of accelerated aging. *Biol Psychiatry* 2006;60:432–435.
- Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. *Proc Natl Acad Sci U S A* 2004;101:17312–17315.
- Minamino T, Komuro I. Role of telomere in endothelial dysfunction in atherosclerosis. *Curr Opin Lipidol* 2002;13:537–543.
- Mooradian AD. Mechanisms of age-related endocrine alterations: Part I. *Drugs Aging* 1993;3:81–97.
- Nair NP, Hariharasubramanian N, Pilapil C, et al. Plasma melatonin—an index of brain aging in humans? *Biol Psychiatry* 1986;21:141–150.
- Blackman MR. Age-related alterations in sleep quality and neuroendocrine function: Interrelationships and implications. *JAMA* 2000;284:879–881.
- Noth RH, Mazzaferri EL. Age and the endocrine system. *Clin Geriatr Med* 1985;1:223–250.
- Sato R, Maesawa C, Fujisawa K, et al. Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. *Gut* 2004;53:1001–1009.
- Meeke AK, Sommerfeld HJ, Coffey DS. Telomerase is activated in the prostate and seminal vesicles of the castrated rat. *Endocrinology* 1996;137:5743–5746.
- Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. *Diabetes Metab* 2001;27(5pt1):535–542.
- Verzijl N, DeGroot J, Ben ZC, et al. Cross-linking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: A possible mechanism through which age is a risk factor for osteoarthritis. *Arthritis Rheum* 2002;46:114–123.

33. Ziemann SJ, Kass DA. Advanced glycation endproduct cross-linking in the cardiovascular system: Potential therapeutic target for cardiovascular disease. *Drugs* 2004;64:459–470.
34. Munch G, Thome J, Foley P, et al. Advanced glycation endproducts in aging and Alzheimer's disease. *Brain Res Brain Res Rev* 1997;23(1–2):134–143.
35. Bellows JG, Bellows RT. Cross-linkage theory of senile cataracts. *Ann Ophthalmol* 1976;8:129–135.
36. Heilbronn LK, de Jonge L, Frisard MI, et al., and the Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. *JAMA* 2006;295:1539–1548.
37. Lane MA, Baer DJ, Rumpel WV, et al. Calorie restriction lowers body temperature in rhesus monkeys, consistent with a postulated anti-aging mechanism in rodents. *Proc Natl Acad Sci U S A* 1996;93:4159–4164.
38. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. *Proc Natl Acad Sci U S A* 2006;103:10230–10235.
39. Chen WY, Wang DH, Yen RC. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. *Cell* 2005;123:437–448.
40. Bevilacqua L, Ramsey JJ, Hagopian K, et al. Effects of short- and medium-term calorie restriction on muscle mitochondrial proton leak and reactive oxygen species production. *Am J Physiol Endocrinol Metab* 2004;286:E852–E861.
41. Merry BJ. Molecular mechanisms linking calorie restriction and longevity. *Int J Biochem Cell Biol* 2002;34:1340–1354.
42. Lambert AJ, Wang B, Merry BJ. Exogenous insulin can reverse the effects of caloric restriction on mitochondria. *Biochem Biophys Res Commun* 2004;316:1196–1201.
43. Cho CG, Kim HJ, Chung SW, et al. Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. *Exp Gerontol* 2003;38:539–548.
44. Srivastava VK, Miller SD, Busbee DL. Aging and DNA polymerase alpha: Modulation by dietary restriction. *J Nutr Health Aging* 1999;3:111–120.
45. Raffoul JJ, Guo Z, Soofi A, Heydari AR. Caloric restriction and genomic stability. *J Nutr Health Aging* 1999;3:102–110.
46. Shimokawa I, Higami Y. Leptin signaling and aging: Insight from caloric restriction. *Mech Ageing Dev* 2001;122:1511–1519.
47. Colotti C, Cavallini G, Vitale RL, et al. Effects of aging and anti-aging caloric restrictions on carbonyl and heat shock protein levels and expression. *Biogerontology* 2005;6:397–406.
48. Grossman R. The role of dimethylaminoethanol in cosmetic dermatology. *Am J Clin Dermatol* 2005;6:39–47.
49. Terman A, Brunk UT. Oxidative stress, accumulation of biological “garbage,” and aging. *Antioxid Redox Signal* 2006;8(1–2):197–204.
50. Nagy I, Nagy K. On the role of cross-linking of cellular proteins in aging. *Mech Ageing Dev* 1980;14(1–2):245–251.
51. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab* 1984;59:551–555.
52. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: A review of human studies. *Eur J Endocrinol* 2004;151:1–14.
53. Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: A randomized, controlled trial. *J Clin Endocrinol Metab* 2006;91:2986–2993.
54. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. *JAMA* 2004;10;292:2243–2248.
55. Martina V, Benso A, Gigliardi VR, et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. *Clin Endocrinol (Oxf)* 2006;64:260–264.
56. Moriyama Y, Yasue H, Yoshimura M. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. *J Clin Endocrinol Metab* 2000;85:1834–1840.
57. Villareal D, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. *Am J Physiol Endocrinol Metab* 2006;291:E1003–E1008.
58. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. *Arch Gen Psychiatry* 2005;62:154–162.
59. Ceda GP, Dall'Aglio E, Maggio M, et al. Clinical implications of the reduced activity of the GH-IGF-I axis in older men [proceedings]. *J Endocrinol Invest* 2005;28(11suppl):96–100.
60. Yang AL, Chao JL, Lee SD. Altered insulin-mediated and insulin-like growth factor-1-mediated vasorelaxation in aortas of obese Zucker rats. *Int J Obes (Lond)* 2006 May 9; e-pub ahead of print.
61. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. *Sci World J* 2006;6:53–80.
62. Onder G, Liperoti R, Russo A, et al. Body mass index, free insulin growth factor 1 and physical function among older adults: Results from the iSIRENTE study. *Am J Physiol Endocrinol Metab* 2006;291:E829–E834.
63. Zhou JN, Liu RY, van Heerikhuizen J, et al. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. *J Pineal Res* 2003;34:11–16.
64. Suzen S. Recent developments of melatonin related antioxidant compounds. *Comb Chem High Throughput Screen* 2006;9:409–419.
65. Srinivasan V, Maestroni G, Cardinali D, et al. Melatonin, immune function and aging. *Immun Ageing* 2005;2:17.
66. Currier NL, Sun LZ, Miller SC. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. *J Neuroimmunol* 2000;104:101–108.
67. Leon J, Acuna-Castroviejo D, Escames G, et al. Melatonin mitigates mitochondrial malfunction. *J Pineal Res* 2005;38:1–9.
68. Srinivasan V, Pandi-Perumal SR, Maestroni GJ. Role of melatonin in neurodegenerative diseases. *Neurotox Res* 2005;7:293–318.
69. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: The neuroendocrine/circadian melatonin signal. *Endocrine* 2005;27:179–188.
70. Blask DE, Dauchy RT, Sauer LA, Krause JA, et al. Light during darkness, melatonin suppression and cancer progression. *Neuro Endocrinol Lett* 2002 Jul;23(suppl2):52–56.
71. Jackson MC, Lenney JF. The distribution of carnosine and related dipeptides in rat and human tissues. *Inflamm Res* 1996;45:132–135.
72. Sturenburg HJ. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases. *Biochemistry (Mosc)* 2000;65:862–865.
73. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: A review. *Curr Med Chem* 2005;12:2293–2315.
74. Shao L, Li QH, Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. *Biochem Biophys Res Commun* 2004 Nov 12;324:931–936.
75. Hipkiss AR. Would carnosine or a carnivorous diet help suppress aging and associated pathologies? *Ann N Y Acad Sci* 2006;1067:369–374.
76. Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a natural anti-senescence drug for human beings. *Biochemistry (Mosc)* 2000;65:869–871.
77. Li F, Chong ZZ, Maiese K. Cell life versus cell longevity: The mysteries surrounding the NAD⁺ precursor nicotinamide. *Curr Med Chem* 2006;13:883–895.
78. Matuoka K, Chen KY, Takenawa T. Rapid reversion of aging phenotypes by nicotinamide through possible modulation of histone acetylation. *Cell Mol Life Sci* 2001;58:2108–2116.
79. Morris MC, Evans DA, Bienias JL, et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. *J Neurol Neurosurg Psychiatry* 2004;75:1093–1099.
80. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. *Am J Cardiol* 1998;82(12A):18U–23U;discussion 39U–41U.
81. Wieneke H, Schmermund A, Erbel R. Niacin—an additive therapeutic approach for optimizing lipid profile [in German]. *Med Klin (Munich)* 2005;100:186–192.
82. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. *Mol Aspects Med* 1997;18(suppl):S159–S168.

83. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. *South Med J* 2001;94:1112–1117.
84. Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. *Cardiovasc Drugs Ther* 1998;12:347–353.
85. Shults CW. Coenzyme Q10 in neurodegenerative diseases. *Curr Med Chem* 2003;10:1917–1921.
86. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. *Neurology* 2005;64:713–715.
87. Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. *Biochem Biophys Res Commun* 1993;192:241–245.
88. Labinskyy N, Csiszar A, Veress G, et al. Vascular dysfunction in aging: Potential effects of resveratrol, an anti-inflammatory phytoestrogen. *Curr Med Chem* 2006;13:989–996.
89. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. *Mol Nutr Food Res* 2005;49:405–430.
90. Bradamante S, Barengi L, Villa A. Cardiovascular protective effects of resveratrol. *Cardiovasc Drug Rev* 2004;22:169–188.
91. Anekonda TS. Resveratrol—A boon for treating Alzheimer's disease? *Brain Res Brain Res Rev* 2006;52:316–326.
92. Lu SC. Regulation of hepatic glutathione synthesis: Current concepts and controversies. *FASEB J* 1999;13:1169–1183.
93. Samiec PS, Drews-Botsch C, Flagg EW, et al. Glutathione in human plasma: Decline in association with aging, age-related macular degeneration, and diabetes. *Free Radic Biol Med* 1998;24:699–704.
94. Bains JS, Shaw CA. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. *Brain Res Brain Res Rev* 1997;25:335–358.
95. Jones DP. Extracellular redox state: Refining the definition of oxidative stress in aging. *Rejuvenation Res* 2006;9:169–181.
96. Bonnefoy M, Draï J, Kostka T. Antioxidants to slow aging, facts and perspectives [in French]. *Presse Med* 2002;31:1174–1184.
97. Alvarado C, Alvarez P, Puerto M, et al. Dietary supplementation with antioxidants improves functions and decreases oxidative stress of leukocytes from prematurely aging mice. *Nutrition* 2006;22(7–8):767–777.
98. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins: Vitamins E and C, beta-carotene, and other carotenoids. *Ann N Y Acad Sci* 1992;669:7–20.
99. Ko JK, Lam FY, Cheung AP. Amelioration of experimental colitis by *Astragalus membranaceus* through anti-oxidation and inhibition of adhesion molecule synthesis. *World J Gastroenterol* 2005;11:5787–5794.
100. Zhang WD, Chen H, Zhang C, et al. Astragaloside IV from *Astragalus membranaceus* shows cardioprotection during myocardial ischemia in vivo and in vitro. *Planta Med* 2006;72:4–8.
101. Shao BM, Xu W, Dai H, et al. A study on the immune receptors for polysaccharides from the roots of *Astragalus membranaceus*, a Chinese medicinal herb. *Biochem Biophys Res Commun* 2004;320:1103–1111.
102. Lei H, Wang B, Li WP, et al. Anti-aging effect of astragalosides and its mechanism of action. *Acta Pharmacol Sin* 2003;24:230–234.
103. Dubey AK, Shankar PR, Upadhyaya D, Deshpande VY. *Ginkgo biloba*—an appraisal. *Kathmandu Univ Med J (KUMJ)* 2004;2:225–229.
104. Zhou W, Chai H, Lin PH, et al. Clinical use and molecular mechanisms of action of extract of *Ginkgo biloba* leaves in cardiovascular diseases. *Cardiovasc Drug Rev* 2004;22:309–319.
105. Bidzan L, Biliekiewicz A, Turczynski J. Preliminary assessment of *Ginkgo biloba* (Ginkofar) in patients with dementia [in Polish]. *Psychiatr Pol* 2005;39:559–566.

Chris D. Meletis, N.D., is a naturopathic doctor at Beaverton Naturopathic Medicine, an integrative medicine clinic in Portland, Oregon, and an associate professor of natural pharmacology at the National College of Naturopathic Medicine, also in Portland. **Nieske Zabriskie, N.D.**, is a naturopathic doctor in Beaverton, Oregon.

To order reprints of this article, write to or call: Karen Ballen, *ALTERNATIVE & COMPLEMENTARY THERAPIES*, Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle NY 10801, (914) 740-2100.